• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing

tetano

Editor, Senior Moderator
Nat Biotechnol. 2012 May 27. doi: 10.1038/nbt.2214. [Epub ahead of print]
Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing.
Whitehead TA, Chevalier A, Song Y, Dreyfus C, Fleishman SJ, De Mattos C, Myers CA, Kamisetty H, Blair P, Wilson IA, Baker D.
Source

1] Department of Biochemistry, University of Washington, Seattle, Washington, USA. [2] Department of Chemical Engineering and Materials Science, Michigan State University, East Lansing, Michigan, USA (T.A.W.) and Department of Biological Chemistry, Weizmann Institute of Science, Rehovot, Israel (S.J.F.). [3].
Abstract

We show that comprehensive sequence-function maps obtained by deep sequencing can be used to reprogram interaction specificity and to leapfrog over bottlenecks in affinity maturation by combining many individually small contributions not detectable in conventional approaches. We use this approach to optimize two computationally designed inhibitors against H1N1 influenza hemagglutinin and, in both cases, obtain variants with subnanomolar binding affinity. The most potent of these, a 51-residue protein, is broadly cross-reactive against all influenza group 1 hemagglutinins, including human H2, and neutralizes H1N1 viruses with a potency that rivals that of several human monoclonal antibodies, demonstrating that computational design followed by comprehensive energy landscape mapping can generate proteins with potential therapeutic utility.

PMID:
22634563
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22634563
 
Back
Top Bottom